Snake antivenoms: Heterologous and polyclonal antisera

Journal of Toxicology - Toxin Reviews

Volumn 22, Issue 1, 2003, Pages 1-14

  Chulasugandha, Pannipa ^a  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Heterologous; Polyclonal antisera; Snake antivenoms

Indexed keywords

ANTIBODY; POLYCLONAL ANTISERUM; PROTEIN; SNAKE VENOM ANTISERUM;

ANIMAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG PURITY; DRUG SYNTHESIS; ECONOMIC ASPECT; ENVENOMATION; HUMAN; PREVENTIVE HEALTH SERVICE; REVIEW; SERUM; SIDE EFFECT; SNAKEBITE; SPECIES;

ANIMALIA; SERPENTES;

EID: 0037237362     PISSN: 07313837     EISSN: None     Source Type: Journal    
DOI: 10.1081/TXR-120019561     Document Type: Review

References (41)

1. Angulo, Y., Estrada, R., Gutierrez, J. M. (1997). Clinical and laboratory alterations in horses during immunization with snake venoms for the production of polyvalent (Crotalinae) antivenom. Toxicon 35:81-90.
2. Aung, W., Pakmanee, N., Khow, O., Nambut, C., Sitprija, V. (2001). Cross neutralization of the lethal activities of Myanmar and Thai Russell's viper venoms by Thai and Myanmar antivenoms. J. Nat. Toxins 10:335-342.
3. Carroll, S. B., Thalley, B. S., Theakston, R. D. G., Laing, G. (1992). Comparison of the purity and efficacy of affinity purified avian antivenoms with commercial equine crotalid antivenoms. Toxicon 30:1017-1025.
4. Chanutin, A., Curnish, R. R. (1960). The precipitation of plasma proteins by short chain fatty acids. Arch. Biochem. Biophys. 89:218-220.
5. Chippaux, J. P., Goyffon, M. (1998). Venoms, antivenoms and immunotherapy. Toxicon 36:823-846.
6. Consroe, P., Egen, N. B., Russell, F. E., Gerrish, K., Smith, D. C., Sidki, A., Landon, J. T. (1995). Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice. Am. J. Trop. Med. Hyg. 53:507-510.
7. 2 activity. Toxicon 20:563-569.
8. Davis, B. D., Kabat, E. A., Harris, A., Moore, D. H. (1944). The anti-complementary activity of serum gamma globulin. J. Immunol. 49: 223-233.
9. 2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield. Toxicon 27:297-303.
10. Elgert, K. D. (1996). Immunology: Understanding the Immune System. New York: Wiley-Liss, Inc. pp. 46-57; 269-290.
11. Freifelder, D. (1982). Physical biochemistry. Applications to Biochemistry and Molecular Biology. New York: W.H. Freeman and Company, pp. 216-322.
12. Freitas, T. V., Frezard, F. (1997). Encapsulation of native crotoxin in liposomes: a safe approach for the production of antivenom and vaccination against Crotalus durissus terrificus venom. Toxicon 35:91-100.
13. 2 antivenoms. An example: new polyvalent european viper antivenom (equine). In: Envenomings and Their Treatments. Bon, C., Goyffon, M., eds. Lyon: Fondation Marcel Merieux, pp. 161-172.
14. Gronski, P., Seiler, F. R., Schwick, H. G. (1991). Discovery of antitoxins and development of antibody preparations for clinical uses from 1890 to 1990. Mol. Immunol. 28:1321-1332.
15. Gutierrez, J. M., Avila, C., Rojas, E., Cerdas, L. (1988). An alternative in vitro method for testing the potency of the polyvalent antivenom produced in Costa Rica. Toxicon 26:411-413.
16. Hanlon, C. A., Niezgoda, M., Morrill, P. A., Rupprecht, C. E. (2001). The incurable wound revisited. Vaccine 19:2273-2279.
17. Jimenez-Porras, J. M. (1964). Intraspecific variations in composition of venom of the jumping viper, Bothrops nummifera. Toxicon 2:187.
18. Jimenez-Porras, J. M. (1964). Venom proteins of the fer-de-lance, Bothrops atrox, from Costa Rica. Toxicon 2:155.
19. Karlson-Stiber, C., Persson, H., Heath, A., Smith, D., Al-Abdulla, I. H., Sjostrom, L. (1997). First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. J. Int. Med. 241:53-58.
20. Krifi, M. N., El Ayeb, M., Dellagi, K. (1999). The improvement and standardization of antivenom production in developing countries: comparing antivenom quality, therapeutical efficiency and cost. J. Venom. Anim. Toxins 5:128-141.
21. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
22. Leon, G., Valverde, J. M., Rojas, G., Lomonte, B., Gutierrez, J. M. (2000). Comparative study on the ability of IgG and Fab sheep antivenoms to neutralize local hemorrhage, edema and myonecrosis induced by Bothrops asper (terciopelo) snake venom. Toxicon 38: 233-244.
23. 2 antivenoms in the neutralization of hemorrhagic activity of Vipera berus snake venom in mice. Toxicon 34:1197-1202.
24. Meyer, W. P., Habib, A. G., Onayade, A. A., Yakubu, A., Smith, D. C., Nasidi, A., Daudu, I. J., Warrell, D. A., Theakston, R. D. G. (1997). First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (IPSER) Africa antivenom. Am. J. Trop. Med. Hyg. 56:291-300.
25. Morais, J. F., de Freitas, M. C. W., Yamaguchi, I. K., dos Santos, M. C., Dias da Silva, W. (1994). Snake antivenoms from hyperimmunized horses: comparison of the antivenom activity and biological properties of their whole IgG and F(ab′)2 fragments. Toxicon 32:725-734.
26. Moroz, C., Grotto, L., Goldblum, N., de Vries, A. (1966). Enhancement of immunogenicity of snake venom neurotoxins. In: Russell, F. E., Saunders, P. R., eds. Animal Toxins. Oxford: Pergamon Press, pp. 299-302.
27. Otero, R., Gutierrez, J. M., Rojas, G., Nunez, V., Diaz, A., Miranda, E., Uribe, A. F., Silva, J. F., Ospina, J. G., Medina, Y., Toro, M. F., Garcia, M. E., Leon, G., Garcia, M., Lizano, S., De La Torre, J., Marquez, J., Mena, Y., Gonzalez, N., Arenas, L. C., Puzon, A., Blanco, N., Sierra, A., Espinal, M. E., Arboleda, M., Jimenez, J. C., Ramirez, P., Diaz, M., Guzman, M. C., Barros, J., Henao, S., Ramirez, A., Macea, U., Lozano, R. (1999). A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon 37:895-908.
28. Pope, C. G. (1938). Disaggregation of proteins by enzymes. Br. J. Exp. Pathol. 19:245-251.
29. Progress in the Characterization of Venoms and Standardization of Antivenoms. (1981). Geneva: WHO Offset Publication No. 58, pp. 9-10.
30. Rojas, G., Espinoza, M., Lomonte, B., Gutierrez, J. M. (1990). Effect of storage temperature on the stability of the liquid polyvalent antivenom produced in Costa Rica. Toxicon 28:101-105.
31. Rojas, G., Vargas, M., Robles, A., Gutierrez, J. M. (1993). Turbidity of hyperimmune equine antivenom: the role of phenol and serum lipoproteins. Toxicon 31:61-66.
32. Rojas, G., Jimenez, J. M., Gutierrez, J. M. (1994). Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 32:351-363.
33. Smith, E. L., Hill, R. L., Lehman, I. R., Lefkowitz, R. J., Handler, P., White, A. (1983). Principles of Biochemistry: General Aspects. Tokyo: Mc-Graw-Hill International Book Company, pp. 161-174.
34. Smith, D. C., Reddi, K. R., Laing, G., Theakston, R. D. G., Landon, J. (1992). An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon 30:865-871.
35. Steinbuch, M., Audran, R. (1969). The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch. Biochem. Biophys. 134:279-284.
36. Taranta, A., Franklin, E. C. (1961). Complement fixation by antibody fragments. Science 134:1981-1982.
37. Theakston, R. D. G., Jane Lloy-Jones, M., Reid, H. A. (1977). Micro-elisa for detecting and assaying snake venom and venom-antibody. Lancet Sept. 24:639-641.
38. Theakston, R. D. G., Warrell, D. A. (1991). Antivenoms: a list of hyperimmune sera currently available for the treatment of envenoming by bites and stings. Toxicon 29:1419-1470.
39. Tijssen, P. (1985). In: Burdon, R. H., van Knippenberg, P. H., eds. Practice and Theory of Enzyme Immunoassays. Laboratory Techniques in Biochemistry and Molecular Biology. Amsterdam: Elsevier, pp. 39-59; 95-120.
40. Wilde, H. (2001). What are today's orphaned vaccines. Clin. Infect. Dis. 33:648-650.
41. Wilde, H., Thipkong, P., Sitprija, V., Chaiyabutr, N. (1996). Heterologous antisera and antivenins are essential biologicals. Perspectives on a worldwide crisis. Ann. Intern. Med. 125:233-236.